Literature DB >> 24764293

Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.

Simon Neumann1, Jan Hasenauer2, Nadine Pollak1, Peter Scheurich3.   

Abstract

The cytokine TNF-related apoptosis-inducing ligand (TRAIL) and its cell membrane receptors constitute an elaborate signaling system fulfilling important functions in immune regulation and tumor surveillance. Activation of the death receptors TRAILR1 and TRAILR2 can lead to apoptosis, whereas TRAILR3 and TRAILR4 are generally referred to as decoy receptors, which have been shown to inhibit TRAIL-induced apoptosis. The underlying molecular mechanisms, however, remain unclear. Alike other members of the TNF receptor superfamily, TRAIL receptors contain a pre-ligand binding assembly domain (PLAD) mediating receptor oligomerization. Still, the stoichiometry of TRAIL receptor oligomers as well as the issue of whether the PLAD mediates only homotypic or also heterotypic interactions remained inconclusive until now. Performing acceptor-photobleaching FRET studies with receptors 1, 2, and 4, we demonstrate interactions in all possible combinations. Formation of dimers was shown by chemical cross-linking experiments for interactions of TRAILR2 and heterophilic interactions between the two death receptors or between either of the death receptors and TRAILR4. Implications of the demonstrated receptor-receptor interactions on signaling were investigated in suitable cellular models. Both apoptosis induction and activation of the transcription factor NFκB were significantly reduced in the presence of TRAILR4. Our experimental data combined with mathematical modeling show that the inhibitory capacity of TRAILR4 is attributable to signaling-independent mechanisms, strongly suggesting a reduction of signaling competent death receptors through formation heteromeric receptor complexes. In summary, we propose a model of TRAIL receptor interference driven by PLAD-mediated formation of receptor heterodimers on the cell membrane.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apoptosis; Fluorescence Resonance Energy Transfer (FRET); Receptor; Signaling; Trail

Mesh:

Substances:

Year:  2014        PMID: 24764293      PMCID: PMC4047423          DOI: 10.1074/jbc.M114.559468

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Authors:  A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

2.  Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.

Authors:  J Mongkolsapaya; J M Grimes; N Chen; X N Xu; D I Stuart; E Y Jones; G R Screaton
Journal:  Nat Struct Biol       Date:  1999-11

3.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

Authors:  F K Chan; H J Chun; L Zheng; R M Siegel; K L Bui; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

4.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.

Authors:  R M Siegel; J K Frederiksen; D A Zacharias; F K Chan; M Johnson; D Lynch; R Y Tsien; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

5.  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.

Authors:  R D Meng; E R McDonald; M S Sheikh; A J Fornace; W S El-Deiry
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

6.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.

Authors:  S G Hymowitz; H W Christinger; G Fuh; M Ultsch; M O'Connell; R F Kelley; A Ashkenazi; A M de Vos
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

7.  Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases.

Authors:  N Harper; S N Farrow; A Kaptein; G M Cohen; M MacFarlane
Journal:  J Biol Chem       Date:  2001-07-18       Impact factor: 5.157

8.  Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death.

Authors:  D C Huang; S Cory; A Strasser
Journal:  Oncogene       Date:  1997-01-30       Impact factor: 9.867

9.  Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction.

Authors:  Anja Krippner-Heidenreich; Fabian Tübing; Susanne Bryde; Sylvia Willi; Gudrun Zimmermann; Peter Scheurich
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

Review 10.  Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.

Authors:  K Azijli; B Weyhenmeyer; G J Peters; S de Jong; F A E Kruyt
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

View more
  20 in total

1.  NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL.

Authors:  Yan Wang; Qiong Lei; Cangjie Shen; Nan Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-04       Impact factor: 3.333

2.  Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand.

Authors:  Nagamani Vunnam; Sophia Szymonski; Petra Hirsova; Gregory J Gores; Jonathan N Sachs; Benjamin J Hackel
Journal:  Biochemistry       Date:  2020-09-30       Impact factor: 3.162

Review 3.  Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.

Authors:  Kelly Xue Jing Jong; Elsa Haniffah Mejia Mohamed; Zaridatul Aini Ibrahim
Journal:  Apoptosis       Date:  2022-10-07       Impact factor: 5.561

Review 4.  Principles of antibody-mediated TNF receptor activation.

Authors:  H Wajant
Journal:  Cell Death Differ       Date:  2015-08-21       Impact factor: 15.828

Review 5.  Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.

Authors:  Anna-Laura Kretz; Silvia von Karstedt; Andreas Hillenbrand; Doris Henne-Bruns; Uwe Knippschild; Anna Trauzold; Johannes Lemke
Journal:  Cancers (Basel)       Date:  2018-03-18       Impact factor: 6.639

Review 6.  Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.

Authors:  Olivier Micheau
Journal:  Int J Mol Sci       Date:  2018-03-02       Impact factor: 5.923

7.  TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.

Authors:  Xiaojie Yu; Sonya James; James H Felce; Blanka Kellermayer; David A Johnston; H T Claude Chan; Christine A Penfold; Jinny Kim; Tatyana Inzhelevskaya; C Ian Mockridge; Yasunori Watanabe; Max Crispin; Ruth R French; Patrick J Duriez; Leon R Douglas; Martin J Glennie; Mark S Cragg
Journal:  Commun Biol       Date:  2021-06-23

Review 8.  Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.

Authors:  U Bertsch; C Röder; H Kalthoff; A Trauzold
Journal:  Cell Death Dis       Date:  2014-08-28       Impact factor: 8.469

Review 9.  Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).

Authors:  Mohammed I Y Elmallah; Olivier Micheau
Journal:  Mar Drugs       Date:  2015-11-13       Impact factor: 5.118

10.  TNFR/TNF-α signaling pathway regulates apoptosis of alveolar macrophages in coal workers' pneumoconiosis.

Authors:  Qing-Zeng Qian; Xiang-Ke Cao; Hai-Yan Liu; Guo-Ying Zheng; Qing-Qiang Qian; Fu-Hai Shen
Journal:  Oncotarget       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.